Literature DB >> 31173552

TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps.

Joseph A Sparano1, Robert Gray1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31173552      PMCID： PMC6881095          DOI： 10.1200/JCO.19.00828

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

Authors:  Gong Tang; Steven Shak; Soonmyung Paik; Stewart J Anderson; Joseph P Costantino; Charles E Geyer; Eleftherios P Mamounas; D Lawrence Wickerham; Norman Wolmark
Journal:  Breast Cancer Res Treat       Date:  2011-01-11       Impact factor: 4.872

2.  Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk.

Authors:  Mitch Dowsett; Nicholas Turner
Journal:  J Clin Oncol       Date:  2019-02-11       Impact factor: 44.544

3.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

4.  Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

Authors:  Lori J Goldstein; Robert Gray; Sunil Badve; Barrett H Childs; Carl Yoshizawa; Steve Rowley; Steven Shak; Frederick L Baehner; Peter M Ravdin; Nancy E Davidson; George W Sledge; Edith A Perez; Lawrence N Shulman; Silvana Martino; Joseph A Sparano
Journal:  J Clin Oncol       Date:  2008-08-04       Impact factor: 44.544

5.  Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

Review 6.  Development of the 21-gene assay and its application in clinical practice and clinical trials.

Authors:  Joseph A Sparano; Soonmyung Paik
Journal:  J Clin Oncol       Date:  2008-02-10       Impact factor: 44.544

7.  Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Authors:  Ulrike Nitz; Oleg Gluz; Matthias Christgen; Ronald E Kates; Michael Clemens; Wolfram Malter; Benno Nuding; Bahriye Aktas; Sherko Kuemmel; Toralf Reimer; Andrea Stefek; Fatemeh Lorenz-Salehi; Petra Krabisch; Marianne Just; Doris Augustin; Cornelia Liedtke; Calvin Chao; Steven Shak; Rachel Wuerstlein; Hans H Kreipe; Nadia Harbeck
Journal:  Breast Cancer Res Treat       Date:  2017-06-29       Impact factor: 4.872

8.  Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.

Authors:  Salomon M Stemmer; Mariana Steiner; Shulamith Rizel; David B Geffen; Bella Nisenbaum; Tamar Peretz; Lior Soussan-Gutman; Avital Bareket-Samish; Kevin Isaacs; Ora Rosengarten; Georgeta Fried; Debbie McCullough; Christer Svedman; Steven Shak; Nicky Liebermann; Noa Ben-Baruch
Journal:  NPJ Breast Cancer       Date:  2017-09-08

9.  21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.

Authors:  Charles E Geyer; Gong Tang; Eleftherios P Mamounas; Priya Rastogi; Soonmyung Paik; Steven Shak; Frederick L Baehner; Michael Crager; D Lawrence Wickerham; Joseph P Costantino; Norman Wolmark
Journal:  NPJ Breast Cancer       Date:  2018-11-14
  9 in total
  2 in total

1.  Whole-Transcriptome Profiling on Small FFPE Samples: Which Sequencing Kit Should Be Used?

Authors:  Marc Hilmi; Lucile Armenoult; Mira Ayadi; Rémy Nicolle
Journal:  Curr Issues Mol Biol       Date:  2022-05-13       Impact factor: 2.976

2.  The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.

Authors:  Valerie E Crolley; Husam Marashi; Shabbir Rawther; Bhawna Sirohi; Marina Parton; Janine Graham; Anup Vinayan; Stephanie Sutherland; Anne Rigg; Anshu Wadhawan; Catherine Harper-Wynne; Emma Spurrell; Hannah Bond; Fharat Raja; Judy King
Journal:  Breast Cancer Res Treat       Date:  2020-03-13       Impact factor: 4.872
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.